Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 MARKET APPLICATION COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 MERGERS AND ACQUISITION
3.2 PIPELINE ANALYSIS FOR GERMANY POST-TRAUMATIC STRESS DISORDER MARKET
3.2.1 RECENT APPROVALS
3.3 PESTEL ANALYSIS
3.4 PORTER'S FIVE FORCES MODEL
4 REGULATIONS OF GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET
4.1 REGULATORY AND DRUG APPROVAL SCENARIO IN GERMANY
4.2 APPROVAL FRAMEWORK
4.2.1 CLINICAL PRACTICE
4.2.2 MARKETING AUTHORIZATION
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 DRUG TREATMENT RATE BY MATURED MARKETS
5.1.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE
5.1.3 KEY PRICING STRATEGIES
5.1.4 KEY PATIENT ENROLLMENT STRATEGIES
6 EPIDEMIOLOGY
6.1 HISTORIC PTSD POOL
6.2 PRESENT PTSD POOL
6.3 FURURE PTSD POOL
6.4 PREVALENCE OF DISSOCIATIVE PTSD BY COUNTRY
6.5 PREVALENCE OF UNCOMPLICATED PTSD BY COUNTRY
6.6 PREVALENCE OF COMORBID PTSD BY COUNTRY
6.7 TREATMENT RATE
7 INTRODUCTION
7.1 OVERVIEW
7.2 IMPACT OF UKRAINE AND RUSSIA WAR ON GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET
7.3 IMPACT ANALYSIS ON DEMAND
7.4 CONCLUSION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF PTSD.
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN THE DIAGNOSIS AND TREATMENT OF PTSD.
8.1.3 THE INCREASING INCIDENCE OF PTSD
8.1.4 INCREASED AWARENESS AMONG PATIENTS AND DOCTORS REGARDING THERAPIES FOR PTSD
8.2 RESTRAINTS
8.2.1 HIGH COST OF THE TREATMENT
8.2.2 SIDE EFFECTS ASSOCIATED WITH PTSD TREATMENT.
8.3 OPPORTUNITIES
8.3.1 RISING HEALTHCARE EXPENDITURE
8.3.2 RISING APPROVALS OF DRUGS
8.3.3 THE RISING NUMBER OF CLINICAL TRIALS IS EXPECTED TO BOOST THE GROWTH OF THE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET
8.4 CHALLENGES
8.4.1 PATENT EXPIRY OF DRUGS
8.4.2 RISING ALTERNATIVE THERAPIES
8.5 UNMEET NEEDS
8.5.1 UNMEET REIMBURSEMENT COST
8.5.2 MENTAL HEALTH STATUS AND SOCIAL CONDITIONS OF ASYLUM SEEKERS
9 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TYPE
9.1 OVERVIEW
9.2 UNCOMPLICATED PTSD
9.3 DISSOCIATIVE PTSD
9.4 COMORBID PTSD
9.5 OTHERS
10 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 PSYCHOTHERAPY
10.2.1 COGNITIVE BEHAVIORAL THERAPY
10.2.2 FAMILY THERAPY
10.2.3 STRESS INOCULATION THERAPY
10.2.4 PROLONGED EXPOSURE THERAPY
10.2.5 OTHERS
10.3 MEDICATION
10.3.1 ANTIDEPRESSANTS
10.3.1.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS
10.3.1.1.1 SERTRALINE
10.3.1.1.2 PAROXETINE
10.3.1.1.3 FLUOXETINE
10.3.1.1.4 CITALOPRAM
10.3.1.1.5 NEFAZODONE
10.3.1.1.6 OTHERS
10.3.1.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
10.3.1.2.1 DULOXETINE
10.3.1.2.2 VENLAFAXINE
10.3.1.2.3 OTHERS
10.3.1.3 TRICYCLIC ANTIDEPRESSANTS
10.3.1.3.1 AMITRIPTYLINE
10.3.1.3.2 IMIPRAMINE
10.3.1.3.3 OTHERS
10.3.2 ANTIPSYCHOTICS
10.3.2.1 QUETIAPINE
10.3.2.2 ARIPIPRAZOLE
10.3.2.3 DIVALPROEX
10.3.2.4 LAMOTRIGINE
10.3.2.5 OTHERS
10.3.3 OTHERS
10.4 SOFTWARE DEVICES
10.4.1 PTSD COACH
10.4.2 PE COACH
10.4.3 CPT COACH
10.4.4 OTHERS
11 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET , BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.4 OTHERS
12 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 ADULTS
12.3 GERIATRICS
12.4 CHILDREN
13 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY END USER
13.1 OVERVIEW
13.2 MENTAL HEALTH CENTERS
13.3 HOSPITALS
13.4 OUTPATIENT CLINICS
13.5 HOME HEALTHCARE
13.6 OTHERS
14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GERMANY
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ABBVIE (2022)
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 VIATRIS INC. (2022)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.3 PFIZER INC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENTS
17.3.5 RECENT DEVELOPMENT
17.4 ELI LILLY AND COMPANY (2022)
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2022)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 ACCORD HEALTHCARE GMBH.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 ALKERMES.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 ASTRAZENECA (2022)
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 AUROBINDO PHARMA.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 CIPLA INC. (2022)
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 DR. REDDY'S LABORATORIES LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 GLAXOSMITHKLINE GROUP OF COMPANIES.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 LUPIN (2022)
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 NOVARTIS AG
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 TEVA PHARMACEUTICAL INDUSTRIES LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 ZYDUS PHARMACEUTICALS, INC. (2022)
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 3 GERMANY PSYCHOTHERAPY IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 4 GERMANY MEDICATION IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 5 GERMANY ANTIDEPRESSANTS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 6 GERMANY SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 7 GERMANY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 GERMANY TRICYCLIC ANTIDEPRESSANTS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 9 GERMANY ANTIPSYCHOTICS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 10 GERMANY SOFTWARE DEVICES IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 11 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 12 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 13 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : SEGMENTATION
FIGURE 2 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DATA TRIANGULATION
FIGURE 3 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DROC ANALYSIS
FIGURE 4 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 8 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DBMR MARKET POSITION GRID
FIGURE 9 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF POST-TRAUMATIC STRESS DISORDER IN POPULATION ARE EXPECTED TO DRIVE THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET IN THE FORECAST PERIOD
FIGURE 12 UNCOPLICATED PTSD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET
FIGURE 14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, 2022
FIGURE 15 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 16 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, 2022
FIGURE 19 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 20 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 21 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 22 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 23 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 24 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 25 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, 2022
FIGURE 27 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 28 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 29 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, 2022
FIGURE 31 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: COMPANY SHARE 2022 (%)
